A recent Nature Health commentary by Robert Beaglehole, Ruth Bonita and Tikki Pang makes a clear and direct argument: the global tobacco-control movement will not make its targeted progress in reducing the global disease burden from smoking unless it embraces tobacco harm reduction (THR). Their article, “Smoke-free nicotine products can accelerate the end of the smoking epidemic,” argues that regulated alternatives such as vaping products, nicotine pouches and heated tobacco should become a formal pillar of global tobacco-control policy.
Nature Health is part of the prestigious Nature portfolio, and the authors are highly-respected within the field of tobacco control and global policy on non-communicable diseases, each having held very senior positions at the World Health Organization (WHO). Their combined reputations make this commentary especially notable in that it respectfully challenges the cautious orthodoxy – hostile to the concept of THR – within parts of the WHO tobacco-control establishment.
Why existing tobacco-control measures may not be enough
The Commentary's core argument is stark: the world has made meaningful progress in reducing smoking prevalence, but momentum is in danger of stalling. Despite implementation of the WHO Framework Convention on Tobacco Control (FCTC), smoking still causes more than seven million deaths annually. The authors contend that conventional demand-reduction measures — taxation, advertising bans and cessation services — are unlikely on their own to eliminate combustible tobacco use at the pace now required to meet global health targets.
A public-health philosophy focused on harm reduction
At Hexis, that’s a point with which we strongly agree. Our focus is on helping to accelerate the transition away from combustible products by supporting innovation, evidence-based regulation and pragmatic public-health approaches. The commentary aligns closely with that philosophy, particularly in its insistence that the objective should be to eliminate harmful tobacco use rather than nicotine consumption in itself.
As the authors write, “it is exposure to smoke from combustion — not nicotine — that drives tobacco-related disease.” That distinction remains surprisingly controversial in parts of the public-health community.
Evidence from international markets Evidence from international markets
The article highlights population-level evidence from Sweden, Japan, New Zealand and the United States, all examples where the uptake of smoke-free alternatives has coincided with accelerated declines in smoking prevalence.
The commentary is also notable for reframing tobacco harm reduction not as an alternative to the FCTC, but as part of it. The authors point out that harm reduction is explicitly recognised within the treaty framework, even if implementation has often been hesitant or inconsistent for political and ideological reasons.
The case for risk-proportionate regulation
In order to realise population health benefits from THR, “risk-proportionate regulation” is required: tough treatment of cigarettes and policies which allow consumers access to lower-risk alternatives. Unfortunately that approach is a long way from reality in many parts of the world.
The communications challenge around nicotine
The Commentary also recognises that there is a significant communications challenge facing regulators and public-health institutions when it comes to THR: widespread distrust of the legacy tobacco industry has helped to fuel “misconceptions about the relative risks of nicotine products” which are “widespread”. The WHO could play a key role in helping to correct those misunderstandings but has, from our perspective, sadly often reinforced them.
Conclusion
A key attraction of this article is its focus on outcomes; the authors appear less interested in ideological purity than in whether smoking prevalence can be reduced dramatically within a generation.
The authors conclude: “The scientific evidence, policy tools and real-world experience needed to end the global smoking epidemic now exist.” They also recognise that the barriers to THR progress are now mostly political. At Hexis we hope that the Commentary will be another step in helping to turn global THR potential into reality.
An investor should consider the investment objectives, risks, and charges and expenses of the fund carefully before investing. A prospectus which contains this and other information about the fund may be obtained by calling 1-800-617-0004, or by clicking here. The prospectus should be read carefully before investing.
Investing involves risk. Principal loss is possible. The Fund is a recently organized entity, giving prospective investors a limited track record on which to base their investment decision. The Fund’s investments will be concentrated in the securities of issuers in the tobacco, or nicotine - related group of industries. The tobacco industry is subject to significant risks and uncertainties that could materially and adversely affect the financial condition and cash flows, of companies operating in it. Investing in foreign securities typically involves more risks than investing in U.S. securities, and includes risks associated with: (i) internal and external political and economic developments – e.g., the political, economic and social policies and structures of some foreign countries may be less stable and more volatile than those in the U.S. or some foreign countries may be subject to trading restrictions or economic sanctions; (ii) trading practices – e.g., government supervision and regulation of foreign securities and currency markets, trading systems and brokers may be less than in the U.S.; (iii) availability of information – e.g., foreign issuers may not be subject to the same disclosure, accounting and financial reporting standards and practices as U.S. issuers; (iv) limited markets – e.g., the securities of certain foreign issuers may be less liquid (harder to sell) and more volatile; and (v) currency exchange rate fluctuations and policies. Investment in emerging market securities involves greater risk than that associated with investment in securities of issuers in developed foreign countries.
Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. A total return swap is a contract in which one party agrees to make periodic payments to another party based on the change in market value of the assets underlying the contract, which may include a specified security, basket of securities, or securities indices during the specified period, in return for periodic payments based on a fixed or variable interest rate or the total return from other underlying assets. The Fund is a non-diversified, investment company under the 1940 Act. Because the Fund is non-diversified, it will invest a greater percentage of its assets in the securities of a limited number of issuers. Investing in medium and small capitalization companies may involve special risks because those companies may have narrower product lines, more limited financial resources, fewer experienced managers, dependence on a few key employees, and a more limited trading market for their stocks, as compared with larger companies. The securities of micro-cap companies may be more volatile in price, have wider spreads between their bid and ask prices, and have significantly lower trading volumes than the securities of larger capitalization companies.
ETFs are subject to risks that the market price of an ETF's shares may trade at a premium or discount to its net asset value, an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact an ETF's ability to sell its shares. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns
The Hexis Active Nicotine Engagement ETF is distributed by Quasar Distributors, LLC
Definitions used on these pages:
R&D: Research and development spend – investment in developing new products, technologies, or capabilities.
M&A: Mergers and acquisitions spend – spending on acquiring or merging with other companies to expand scale, capabilities, or market access.
Capex: Capital expenditure – investment in long-term physical or intangible assets such as facilities, equipment, or infrastructure.
Discounted Cash Flow (DCF) model – a valuation method that estimates a company’s value by discounting its expected future cash flows back to today.
Terminal value – the estimated value of a business beyond the explicit forecast period in a DCF model.
Terminal growth rate – the assumed long-term, steady growth rate used to calculate terminal value.
EV: Enterprise Value – a measure of a company’s total value, calculated as market capitalisation plus net debt
EBITDA: Earnings before interest, taxes, depreciation and amortisation